Bio-Works Technologies Past Earnings Performance
Past criteria checks 0/6
Bio-Works Technologies's earnings have been declining at an average annual rate of -4.9%, while the Medical Equipment industry saw earnings growing at 22.9% annually. Revenues have been growing at an average rate of 24.9% per year.
Key information
-4.9%
Earnings growth rate
2.3%
EPS growth rate
| Medical Equipment Industry Growth | 6.2% |
| Revenue growth rate | 24.9% |
| Return on equity | -65.1% |
| Net Margin | -99.0% |
| Next Earnings Update | 21 Feb 2025 |
Recent past performance updates
Recent updates
Companies Like Bio-Works Technologies (STO:BIOWKS) Are In A Position To Invest In Growth
Dec 25
Companies Like Bio-Works Technologies (STO:BIOWKS) Are In A Position To Invest In Growth
Aug 30We Think Bio-Works Technologies (STO:BIOWKS) Can Afford To Drive Business Growth
Feb 21We Think Bio-Works Technologies (STO:BIOWKS) Can Afford To Drive Business Growth
Oct 25We Think Bio-Works Technologies (STO:BIOWKS) Can Easily Afford To Drive Business Growth
May 10Bio-Works Technologies (STO:BIOWKS) Is In A Strong Position To Grow Its Business
Sep 27Is Bio-Works Technologies (STO:BIOWKS) In A Good Position To Invest In Growth?
May 11Bio-Works Technologies AB (publ) (STO:BIOWKS) Insiders Have Been Selling
Mar 20How Much Are Bio-Works Technologies AB (publ) (STO:BIOWKS) Insiders Taking Off The Table?
Dec 05
Revenue & Expenses Breakdown
How Bio-Works Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 38 | -38 | 65 | 0 |
| 30 Jun 24 | 35 | -47 | 74 | 0 |
| 31 Mar 24 | 39 | -52 | 78 | 0 |
| 31 Dec 23 | 44 | -57 | 82 | 0 |
| 30 Sep 23 | 40 | -54 | 81 | 0 |
| 30 Jun 23 | 45 | -50 | 81 | 0 |
| 31 Mar 23 | 43 | -48 | 78 | 0 |
| 31 Dec 22 | 41 | -45 | 75 | 0 |
| 30 Sep 22 | 38 | -45 | 72 | 0 |
| 30 Jun 22 | 34 | -45 | 70 | 0 |
| 31 Mar 22 | 45 | -29 | 66 | 0 |
| 31 Dec 21 | 56 | -13 | 63 | 0 |
| 30 Sep 21 | 50 | -14 | 58 | 0 |
| 30 Jun 21 | 44 | -15 | 54 | 0 |
| 31 Mar 21 | 25 | -29 | 51 | 0 |
| 31 Dec 20 | 7 | -45 | 49 | 0 |
| 30 Sep 20 | 7 | -42 | 49 | 0 |
| 30 Jun 20 | 7 | -42 | 49 | 0 |
| 31 Mar 20 | 7 | -45 | 51 | 0 |
| 31 Dec 19 | 6 | -42 | 46 | 0 |
| 30 Sep 19 | 6 | -55 | 53 | 0 |
| 30 Jun 19 | 5 | -51 | 49 | 0 |
| 31 Mar 19 | 5 | -41 | 39 | 0 |
| 31 Dec 18 | 7 | -38 | 37 | 0 |
| 30 Sep 18 | 6 | -25 | 27 | 0 |
| 30 Jun 18 | 6 | -22 | 26 | 0 |
| 31 Mar 18 | 7 | -26 | 30 | 0 |
| 31 Dec 17 | 6 | -24 | 29 | 0 |
| 30 Sep 17 | 6 | -20 | 25 | 0 |
| 31 Dec 16 | 6 | -17 | 24 | 0 |
| 31 Dec 15 | 3 | -12 | 17 | 0 |
Quality Earnings: BIOWKS is currently unprofitable.
Growing Profit Margin: BIOWKS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOWKS is unprofitable, and losses have increased over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare BIOWKS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOWKS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).
Return on Equity
High ROE: BIOWKS has a negative Return on Equity (-65.1%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 06:44 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Works Technologies AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Palin | Penser Access |